Stanford



# Everett Meyer

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Medicine - Blood & Marrow Transplantation


**CLINICAL OFFICE (PRIMARY)**

- **Stanford Cancer Center**

  875 Blake Wilbur Dr Clinic F

  MC 6560

  Stanford, CA 94305

  **Tel** (650) 498-6000 **Fax** (650) 498-6159

**ACADEMIC CONTACT INFORMATION**

- **Administrative Contact**

  Joyce Trioano - Administrative Associate

  **Email** jtroiano@stanford.edu

  **Tel** (650) 703-4501


## Bio

### BIO

Research focus in hematopoietic stem cell transplantation and Treg cell immunotherapy, with an emphasis on the treatment of graft-versus-host disease as well as immune tolerance induction for transplantation and autoimmunity.

### CLINICAL FOCUS

- Cancer > Blood and Marrow Transplant
- Hematology

### ACADEMIC APPOINTMENTS

- Professor-Univ Med Line, Medicine - Blood & Marrow Transplantation
- Member, Bio-X
- Member, Maternal & Child Health Research Institute (MCHRI)
- Member, Stanford Cancer Institute
- Member, Wu Tsai Neurosciences Institute

### HONORS AND AWARDS

- Young Investigator Award, American Society of Blood and Marrow Transplantation (2011)
- Amy Streizer Manasevit Scholar, National Donor Marrow Program and American Society for Blood and Marrow Transplantation (2013)
- Beckman Center Technology Grant, Stanford University (2014)
- Career Development Award, JDRF (2017)

### PROFESSIONAL EDUCATION

- Medical Education: Stanford University School of Medicine (2008) CA
- Residency: Stanford University Internal Medicine Residency (2010) CA
- Internship: Stanford University Internal Medicine Residency (2009) CA

- Fellowship: Stanford University Hematology and Oncology Fellowship (2013) CA
- Board Certification: Hematology, American Board of Internal Medicine (2016)

### LINKS

- Meyer Laboratory Website: med.stanford.edu/meyerlab/

## Research & Scholarship

### CURRENT RESEARCH AND SCHOLARLY INTERESTS

Research focus in T cell immunotherapy and T cell immune monitoring using high-throughput sequencing and genomic approaches, with an emphasis on hematopoietic stem cell transplantation, the treatment of graft-versus-host disease and immune tolerance induction.

### CLINICAL TRIALS

- A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies, Recruiting
- Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs., Recruiting
- Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release, Recruiting
- A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant, Not Recruiting
- A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1), Not Recruiting
- Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant, Not Recruiting
- Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel, Not Recruiting
- GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease, Not Recruiting
- Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells, Not Recruiting
- Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell, Not Recruiting
- Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders, Not Recruiting
- Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies, Not Recruiting
- Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies, Not Recruiting
- Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft, Not Recruiting

## Teaching

### STANFORD ADVISEES

**Postdoctoral Research Mentor**

Gabriel Salzman

### GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Immunology (PhD Program)

## Publications

### PUBLICATIONS

- **Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease.** *Blood*
  Meyer, E., Pavlova, A., Villar-Prados, A., Bader, C. S., Xie, B., Muffly, L., Kim, P., Sutherland, K. C., Bharadwaj, S., Dahiya, S., Frank, M. J., Arai, S., Johnston, et al
  2025

- **CAR T-cells in autoimmunity: game changer or stepping stone?** *Blood*
  Mougiakakos, D., Meyer, E., Schett, G.
  2024

- **Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice.** *Bone marrow transplantation*
  Chin, M. M., Tamaresis, J. S., Johnston, L. J., Lowsky, R., Meyer, E., Muffly, L., Shiraz, P., Frank, M. J., Rezvani, A. R., Bharadwaj, S., Weng, W. K., Shizuru, J. A., Arai, et al
  2024

- **Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.** *Blood cancer journal*
  Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S. K., Holmes, T. H., Tamaresis, J., Le, A., Muffly, L. S., Maysel-Auslender, S., Johnston, L., Arai, S., Lowsky, R., Meyer, et al
  2024; 14 (1): 173

- **PHASE 1 TRIAL RESULTS FOR PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES TREATED WITH ORCA-T CELL THERAPY WITH REDUCED INTENSITY CONDITIONING AND SINGLE AGENT TACROLIMUS**
  Villar-Prados, A., Sutherland, K., Negrin, R., Arai, S., Frank, M., Johnston, L., Lowsky, R., Miklos, D., Muffly, L., Dahiya, S., Rezvani, A., Sidana, S., Shiraz, et al
  SPRINGERNATURE.2024: 287-288

- **A RETROSPECTIVE ANALYSIS COMPARING ORCA-T TO POST-TRANSPLANT CYCLOPHOSPHAMIDE BASED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH MATCHED UNRELATED DONORS RECEIVING MYELOABLATIVE CONDITIONING**
  Salhotra, A., Arteaga, A., Oliai, C., Patel, S. S., Pantin, J., Gandhi, A., Dholaria, B., Waller, E. K., Srour, S. A., Pavlova, A., Agodoa, I., McClellan, J., Fernhoff, et al
  SPRINGERNATURE.2024: 237-238

- **Hybrid allogeneic bone marrow transplant rescue approach after acute myelogenous leukaemia relapse in a high-risk patient.** *British journal of haematology*
  Villar-Prados, A., Kennedy, V. E., Meyer, E. H.
  2024

- **Treatment of Acute Myeloid Leukemia With Orca-T**
  Srour, S., Pantin, J., Patel, S., Faramand, R., Gandhi, A., Salhotra, A., Oliai, C., Dholaria, B., Pavlova, A., McClellan, S., Agodoa, I., Li, A., Fernhoff, et al
  CIG MEDIA GROUP, LP.2024: S317-S318

- **Folate Receptor β CAR-Tregs Induce Monocyte Apoptosis and Immune Polarization: Potential for Therapeutic Application in Rheumatoid Arthritis**
  Wu, X., Chen, P., Cruz, M., Jensen, K., Meyer, E.
  WILEY.2024: 3794-3795

- **CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.** *Lancet (London, England)*
  Frank, M. J., Baird, J. H., Kramer, A. M., Srinagesh, H. K., Patel, S., Brown, A. K., Oak, J. S., Younes, S. F., Natkunam, Y., Hamilton, M. P., Su, Y. J., Agarwal, N., Chinnasamy, et al
  2024

- **Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.** *Journal for immunotherapy of cancer*
  Bharadwaj, S., Lau, E., Hamilton, M. P., Goyal, A., Srinagesh, H., Jensen, A., Lee, D., Mallampet, J., Elkordy, S., Syal, S., Patil, S., Latchford, T., Sahaf, et al
  2024; 12 (7)

- **CD39 delineates chimeric antigen receptor regulatory T cell subsets with distinct cytotoxic & regulatory functions against human islets** *FRONTIERS IN IMMUNOLOGY*
  Wu, X., Chen, P., Whitener, R. L., MacDougall, M. S., Coykendall, V. M. N., Yan, H., Kim, Y., Harper, W., Pathak, S., Iliopoulou, B. P., Hestor, A., Saunders, D. C., Spears, et al
  2024; 15: 1415102

- **Treatment of acute myeloid leukemia with Orca-T.**
  Pantin, J., Patel, S. S., Faramand, R., Gandhi, A., Salhotra, A., Oliai, C., Srour, S., Dholaria, B. R., Pavlova, A., McClellan, J., Agodoa, I., Li, A., Fernhoff, et al
  LIPPINCOTT WILLIAMS & WILKINS.2024

- **Management of post-autologous transplant relapse in patients with T-cell lymphomas.** *American journal of hematology*
  Veilleux, O., Socola, F., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Shizuru, J., Meyer, E., Muffly, L., Rezvani, A. R., Shiraz, P., Sidana, S., Dahiya, et al
  2024

- **Precision Delivery of Human Bone Marrow-Derived Mesenchymal Stem Cells Into the Pancreas Via Intra-arterial Injection Prevents the Onset of Diabetes.** *Stem cells translational medicine*
  Primavera, R., Regmi, S., Yarani, R., Levitte, S., Wang, J., Ganguly, A., Chetty, S., Guindani, M., Ricordi, C., Meyer, E., Thakor, A. S.
  2024

- **CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.** *Blood advances*
  Hamilton, M. P., Craig, E., Gentille Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., Ehlinger, Z., Syal, S., Good, Z., Sworder, B., Schroers-Martin, J., Lu, Y., Muffly, et al
  2024

- **CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.** *Leukemia*
  Schultz, L. M., Jeyakumar, N., Kramer, A. M., Sahaf, B., Srinagesh, H., Shiraz, P., Agarwal, N., Hamilton, M., Erickson, C., Jacobs, A., Moon, J., Baggott, C., Arai, et al
  2024

- **Regulatory T cells use heparanase to access IL-2 bound to extracellular matrix in inflamed tissue.** *Nature communications*
  Martinez, H. A., Koliesnik, I., Kaber, G., Reid, J. K., Nagy, N., Barlow, G., Falk, B. A., Medina, C. O., Hargil, A., Zihsler, S., Vlodavsky, I., Li, J. P., Pérez-Cruz, et al
  2024; 15 (1): 1564

- **Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD.** *Blood advances*
  Bader, C. S., Pavlova, A., Lowsky, R., Muffly, L., Shiraz, P., Arai, S., Johnston, L. J., Rezvani, A. R., Weng, W. K., Miklos, D. B., Frank, M. J., Tamaresis, J. S., Agrawal, et al
  2023

- **CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias**
  Hamilton, M. P., Sworder, B. J., Alig, S. K., Good, Z., Boegeholz, J., Schroers-Martin, J., Tamaresis, J., Esfahani, M., Lu, Y., Olsen, M., Liu, C., Ehlinger, Z., Desai, et al
  AMER SOC HEMATOLOGY.2023

- **High Disease-Free Survival in Patients with High-Risk MDS Treated with Orca-T**
  Gandhi, A., Hoeg, R. T., Patel, S. S., Waller, E. K., Pantin, J. M., Oliai, C. H., McClellan, J., Pavlova, A., Agodoa, I., Fernhoff, N. B., Meyer, E. H.
  AMER SOC HEMATOLOGY.2023

- **Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus**
  Villar-Prados, A., Meyer, E. H., Sutherland, K., Negrin, R. S., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Miklos, D. B., Muffly, L. S., Dahiya, S., Rezvani, A. R., Sidana, et al
  AMER SOC HEMATOLOGY.2023

- **Safety and Efficacy of Orca-Q with Haploidentical Donors for the Treatment of Advanced Hematologic Malignancies without the Use of Post-Transplant Cyclophosphamide**
  Srour, S. A., Salhotra, A., Lowsky, R., Hoeg, R. T., Waller, E. K., Pavlova, A., McClellan, J., Fernhoff, N. B., Meyer, E. H., Abedi, M.
  AMER SOC HEMATOLOGY.2023

- **Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies**
  Oliai, C. H., Pantin, J. M., Hoeg, R. T., Muffly, L. S., Patel, S. S., Gandhi, A., Lowsky, R., Salhotra, A., Dholaria, B., Waller, E. K., Srour, S. A., Pavlova, A., Fernhoff, et al
  AMER SOC HEMATOLOGY.2023

- **PRECISION-ENGINEERED CELL THERAPY ORCA-T DEMONSTRATES HIGH RELAPSE-FREE SURVIVAL AT 1 YEAR WHILE REDUCING GRAFT-VERSUS-HOST DISEASE AND TOXICITY**
  Oliai, C., Hoeg, R., Pavlova, A., Gandhi, A., Muffly, L., Mehta, R., Srour, S., Waller, E., Lowsky, R., Patel, S., Dholaria, B., Pantin, J., Salhotra, et al
  SPRINGERNATURE.2023: 230-231

- **RAPID IMMUNE RECONSTITUTION AND ELEVATED REGULATORY T CELL FREQUENCIES IN PATIENTS TREATED WITH ORCA-T**
  Gandhi, A., Killian, M., Pavlova, A., Bader, C., Summers, S., Teque, F., McClellan, J., Fernhoff, N., Meyer, E.
  SPRINGERNATURE.2023: 244

- **Orca-Q Demonstrates Favorable Graft-Versus-Host Disease (GvHD) and Relapse-Free Survival With Haploidentical Donors Without Post-Transplant Cyclophosphamide**
  Srour, S. A., Salhotra, A., Lowsky, R., Hoeg, R. T., Saad, A., Waller, E. K., Pavlova, A., McClellan, J., Fernhoff, N. B., Meyer, E. H., Abedi, M.
  CIG MEDIA GROUP, LP.2023: S537

- **Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease (GvHD) and Toxicity**
  Salhotra, A., Oliai, C., Hoeg, R. T., Gandhi, A., Muffly, L., Srour, S. A., Waller, E., Lowsky, R., Patel, S., Pantin, J., Dholaria, B., Pavlova, A., Fernhoff, et al
  CIG MEDIA GROUP, LP.2023: S316-S317

- **Single cell multi-omics technologies enable human immunogenomics monitoring**
  Ji, X., Miranda, M., Suresh, S., Bader, C., Zoubeidi, A., Meyer, E. H., Maecker, H.
  AMER ASSOC IMMUNOLOGISTS.2023

- **HLA Class I genotype is associated with relapse risk after allogeneic stem cell transplantation for NPM1-mutated AML.** *Transplantation and cellular therapy*
  Narayan, R., Niroula, A., Wang, T., Kuxhausen, M., He, M., Meyer, E., Chen, Y. B., Bhatt, V. R., Beitinjaneh, A., Nishihori, T., Sharma, A., Brown, V. I., Kamoun, et al
  2023

- **FOXP3+ regulatory T cells use heparanase to access IL-2 bound to ECM in inflamed tissues.** *bioRxiv : the preprint server for biology*
  Martinez, H. A., Koliesnik, I., Kaber, G., Reid, J. K., Nagy, N., Barlow, G., Falk, B. A., Medina, C. O., Hargil, A., Vlodavsky, I., Li, J. P., Pérez-Cruz, M., Tang, et al
  2023

- **Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity**
  Oliai, C., Hoeg, R. T., Pavlova, A., Gandhi, A., Muffly, L., Mehta, R. S., Srour, S. A., Waller, E. K., Lowsky, R., Patel, S. S., Dholaria, B., Bachier, C., Pantin, et al
  AMER SOC HEMATOLOGY.2022

- **Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects**
  Hamilton, M. P., Liu-Fei, F. C., Alig, S. K., Tamaresis, J., Esfahani, M., Good, Z., Sworder, B., Schroers-Martin, J., Liu, C., Severinsen, F., Hanson, P. J., Lu, Y., Lowsky, et al
  AMER SOC HEMATOLOGY.2022: 7545-7547

- **The Development of CarhIh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes**
  Philip, S., Srinagesh, H. K., Hamilton, M. P., Gentille, C., Mina, A., Arai, S., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, R. S., Rezvani, A. R., Shiraz, P., Shizuru, et al
  AMER SOC HEMATOLOGY.2022: 12775-12777

- **Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma**
  Bharadwaj, S., Hamilton, M. P., Sahaf, B., Tamaresis, J., Patil, S., Hanson, P. J., Latchford, T., Arai, S., Johnston, L. J., Lowsky, R., Negrin, R. S., Rezvani, A. R., Shizuru, et al
  AMER SOC HEMATOLOGY.2022: 10371-10373

- **Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era**
  Philip, S., Lowsky, R., Johnston, L. J., Arai, S., Meyer, E. H., Negrin, R. S., Rezvani, A. R., Shiraz, P., Shizuru, J. A., Sidana, S., Weng, W., Bharadwaj, S., Frank, et al
  AMER SOC HEMATOLOGY.2022: 4825-4827

- **Rapid Immune Reconstitution and Elevated Regulatory T Cell Frequencies in Patients Treated with Orca-T**
  Meyer, E. H., Killian, M., Pavlova, A., Bader, C., Summers, S., Teque, F., McClellan, J., Fernhoff, N. B.
  AMER SOC HEMATOLOGY.2022: 7656-7657

- **Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide**
  Salhotra, A., Srour, S. A., Hoeg, R. T., Saad, A., Meyer, E. H., Pavlova, A., Waller, E. K., Chao, M., McClellan, J., Fernhoff, N. B., Lowsky, R., Abedi, M.
  AMER SOC HEMATOLOGY.2022: 1865-1866

- **Curative islet and hematopoietic cell transplantation in diabetic mice without toxic bone marrow conditioning.** *Cell reports*
  Chang, C. A., Bhagchandani, P., Poyser, J., Velasco, B. J., Zhao, W., Kwon, H., Meyer, E., Shizuru, J. A., Kim, S. K.
  2022; 41 (6): 111615

- **CT-524 Orca-T, A Precision Engineered Allograft, Results in High GVHD-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies.** *Clinical lymphoma, myeloma & leukemia*
  Meyer, E., Pavlova, A., Gandhi, A., Hoeg, R., Oliai, C., Mehta, R., Srour, S., McGuirk, J., Waller, E., Fernhoff, N., Killian, M. S., Mcclellan, J., Putnam, et al
  2022; 22 Suppl 2: S447

- **Orca-T, A Precision Engineered Allograft, Results in High GVHD-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies**
  Meyer, E., Pavlova, A., Gandhi, A., Hoeg, R., Oliai, C., Mehta, R., Srour, S., McGuirk, J., Waller, E., Fernhoff, N., Killian, M., Mcclellan, J., Putnam, et al
  CIG MEDIA GROUP, LP.2022: S447

- **Achievement of Persistent Mixed Chimerism in Recipients of Matched and Mismatched Living Donor Kidney Transplants in a Tolerance Induction Protocol**
  Scandling, J., Busque, S., Lowsky, R., Pham, T., Hoppe, R., Jensen, K., Shori, A., Wu, H., Pawar, R., Engleman, E., Meyer, E., Strober, S.
  LIPPINCOTT WILLIAMS & WILKINS.2022: S44

- **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era.** *Transplantation and cellular therapy*
  Liang, E. C., Craig, J., Torelli, S., Cunanan, K., Iglesias, M., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R., Rezvani, et al
  2022

- **Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report.** *Transplantation and cellular therapy*
  Bankova, A. K., Caveney, J., Yao, B., Ramos, T. L., Bogeholz, J., Heydari, K., Diaz, N., Jackson, M. L., Lowsky, R., Brown, J. W., Johnston, L., Rezvani, A. R., Frank, et al
  1800

- **Immunoregulatory effects of RGMb in gut inflammation.** *Frontiers in immunology*
  Perez-Cruz, M., Iliopoulou, B. P., Hsu, K., Wu, H., Erkers, T., Swaminathan, K., Tang, S., Bader, C. S., Kambham, N., Xie, B., Dekruyff, R. H., Freeman, G. J., Meyer, et al
  2022; 13: 960329

- **Mgta-145+Plerixafor Provides GCSFFree Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study**
  Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S., Tamaresis, J., Le, A., Muffly, L., Johnston, L. J., Arai, S., Lowsky, R., Meyer, E. H., Rezvani, A. R., Weng, et al
  AMER SOC HEMATOLOGY.2021

- **Outcomes for Myelofibrosis Patients Following Myeloablative Allogeneic Stem Cell Transplantation Using the Orca-T Graft from HLA-Matched Related and Unrelated Donors**
  Arpita, G., Moroz, A., Muffly, L., Shiraz, P., Schachter, L., Fernhoff, N. B., McClellan, J., Negrin, R. S., Gotlib, J., Meyer, E. H.
  AMER SOC HEMATOLOGY.2021: 1819-+

- **Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy** *BLOOD ADVANCES*
  Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffly, L., Zehnder, J., Tamaresis, J., Negrin, R., Johnston, L., Arai, S., Shizuru, J., Lowsky, R., Meyer, et al

2021; 5 (21): 4465-4475

- **Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients.** *Science translational medicine*
  Chen, P. P., Cepika, A., Agarwal-Hashmi, R., Saini, G., Uyeda, M. J., Louis, D. M., Cieniewicz, B., Narula, M., Amaya Hernandez, L. C., Harre, N., Xu, L., Thomas, B. C., Ji, et al
  2021; 13 (617): eabf5264

- **Evaluation of Patient Products with Aberrant Cryopreservation Curve**
  Joaquin, Z., McIntyre, C., Meyer, E., McLeod, M., Diaz, N., Amiri, Z., Lim, L., Bove, R., Patel, R., Prarthna, F.
  WILEY.2021: 97A-98A

- **Development of immunosuppressive myeloid cells to induce tolerance in solid organ and hematopoietic cell transplant recipients.** *Blood advances*
  Jensen, K. P., Hongo, D., Ji, X., Zheng, P., Pawar, R. D., Wu, H., Busque, S., Scandling, J. D., Shizuru, J. A., Lowsky, R., Shori, A., Dutt, S., Waters, et al
  2021

- **Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.** *Blood advances*
  Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., Spiegel, J. Y., Arai, S., Frank, M. J., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, et al
  2021; 5 (16): 3147-3151

- **CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.** *Nature medicine*
  Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J., Iglesias, M., Younes, S., Natkunam, et al
  2021

- **Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.** *Bone marrow transplantation*
  Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., Shiraz, P., Rezvani, A. R., Frank, M. J., Weng, W., Meyer, E., Shizuru, J. A., Arai, et al
  2021

- **Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report**
  Bankova, A., Caveney, J., Ramos, T., Bogeholz, J., Heydari, K., Diaz, N., Jackson, M., Lowsky, R., Brown, J., Johnston, L., Rezvani, A., Frank, M., Muffly, et al
  SPRINGERNATURE.2021: 181

- **Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.**
  Sidana, S., Bankova, A., Hosoya, H., Muffly, L. S., Kumar, S., Johnston, L. J., Lowsky, R., Meyer, E., Rezvani, A., Weng, W., Arai, S., Frank, M., Shiraz, et al
  LIPPINCOTT WILLIAMS & WILKINS.2021

- **Adoptively Transferred, In Vitro-Generated Alloantigen-Specific Type 1 Regulatory T (Tr1) Cells Persist Long-Term In Vivo**
  Cepika, A., Chen, P. P., Agarwal, R., Saini, G., Louis, D. M., Amaya-Hernandez, L. C., Xu, L., Shiraz, P., Tate, K. M., Margittai, D., Bhatia, N., Meyer, E., Bertaina, et al
  CELL PRESS.2021: 73

- **Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.** *Transplantation and cellular therapy*
  Johnsrud, A., Ladha, A., Muffly, L., Shiraz, P., Goldstein, G., Osgood, V., Shizuru, J. A., Johnston, L., Arai, S., Weng, W., Lowsky, R., Rezvani, A. R., Meyer, et al
  2021

- **Using the binary language of IL-2 to prevent GVHD.** *Blood*
  Meyer, E. H.
  2021; 137 (16): 2136–37

- **Generation of recombinant hyperimmune globulins from diverse B-cell repertoires.** *Nature biotechnology*
  Keating, S. M., Mizrahi, R. A., Adams, M. S., Asensio, M. A., Benzie, E., Carter, K. P., Chiang, Y., Edgar, R. C., Gautam, B. K., Gras, A., Leong, J., Leong, R., Lim, et al
  2021

- **Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.** *Transplantation and cellular therapy*
  Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., Frank, M. J., Weng, W., Lowsky, R., Rezvani, A., Meyer, E. H., Negrin, R., Miklos, et al
  2021

- **Tregs and Mixed Chimerism as Approaches for Tolerance Induction in Islet Transplantation** *FRONTIERS IN IMMUNOLOGY*
  Pathak, S., Meyer, E. H.
  2021; 11

- **Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.** *Blood advances*
  Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., Meyer, E., Arai, S., Brown, et al
  2021; 5 (1): 143-155

- **Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma** *BLOOD ADVANCES*
  Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., Meyer, E., Arai, S., Brown, et al
  2021; 5 (1): 143–55

- **Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy.** *Blood advances*
  Johnsrud, A. J., Craig, J., Baird, J. H., Spiegel, J. Y., Muffly, L., Zehnder, J. L., Tamaresis, J. S., Negrin, R. S., Johnston, L., Arai, S., Shizuru, J. A., Lowsky, R., Meyer, et al
  2021

- **Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist.** *eLife*
  Glassman, C. R., Su, L. n., Majri-Morrison, S. S., Winkelmann, H. n., Mo, F. n., Li, P. n., Pérez-Cruz, M. n., Ho, P. P., Koliesnik, I. n., Nagy, N. n., Hnizdilova, T. n., Picton, L. K., Kovar, et al
  2021; 10

- **Identification of Two Subsets of Murine DC1 Dendritic Cells That Differ by Surface Phenotype, Gene Expression, and Function.** *Frontiers in immunology*
  Hongo, D., Zheng, P., Dutt, S., Pawar, R. D., Meyer, E., Engleman, E. G., Strober, S.
  2021; 12: 746469

- **Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
  Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., Rezvani, A., Frank, M. J., Weng, W., Meyer, E., Shizuru, J., Arai, S., Negrin, et al
  2020

- **Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.**
  Lemieux, C., Muffly, L. S., Iberri, D., Rezvani, A., Lowsky, R., Frank, M., Craig, J. K., Liedtke, M., Negrin, R., Weng, W., Meyer, E., Johnston, L. J., Shizuru, et al
  LIPPINCOTT WILLIAMS & WILKINS.2020

- **Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).**
  Tam, E., Iberri, D., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M., Lowsky, R., Rezvani, A., Negrin, R., Meyer, E., Arai, S., Johnston, L. J., Shizuru, et al
  LIPPINCOTT WILLIAMS & WILKINS.2020

- **Massively parallel interrogation and mining of natively paired human TCRαβ repertoires.** *Nature biotechnology*
  Spindler, M. J., Nelson, A. L., Wagner, E. K., Oppermans, N., Bridgeman, J. S., Heather, J. M., Adler, A. S., Asensio, M. A., Edgar, R. C., Lim, Y. W., Meyer, E. H., Hawkins, R. E., Cobbold, et al

2020; 38 (5): 609-619

- **Massively parallel interrogation and mining of natively paired human TCR alpha beta repertoires** *NATURE BIOTECHNOLOGY*
  Spindler, M. J., Nelson, A. L., Wagner, E. K., Oppermans, N., Bridgeman, J. S., Heather, J. M., Adler, A. S., Asensio, M. A., Edgar, R. C., Lim, Y., Meyer, E. H., Hawkins, R. E., Cobbold, et al
  2020

- **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era**
  Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R. S., Rezvani, A., Shiraz, P., Shizuru, J. A., Sidana, S., Weng, W., Cunanan, et al
  ELSEVIER SCIENCE INC.2020: S106

- **Analysis of Whole CDR3 TCR Repertoire after Hematopoietic Stem Cell Transplantation in Two Clinical Cohorts.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
  Shah, O., Tamaresis, J. S., Kenyon, L. J., Xu, L., Zheng, P., Gupta, P., RangarajanK, K., Lee, S., Spellman, S., Nikiforow, S., Zehnder, J., Meyer, E. H.
  2020

- **Tregs and Mixed Chimerism as Approaches for Tolerance Induction in Islet Transplantation.** *Frontiers in immunology*
  Pathak, S., Meyer, E. H.
  2020; 11: 612737

- **High-Parametric Evaluation of Human Invariant Natural Killer T Cells to Delineate Heterogeneity in Allo- and Autoimmunity.** *Blood*
  Erkers, T., Xie, B., Kenyon, L. J., Smith, B., Rieck, M., Jensen, K. P., Ji, X., Basina, M., Strober, S., Negrin, R. S., Maecker, H. T., Meyer, E.
  2020

- **Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal.** *Science translational medicine*
  Busque, S. n., Scandling, J. D., Lowsky, R. n., Shizuru, J. n., Jensen, K. n., Waters, J. n., Wu, H. H., Sheehan, K. n., Shori, A. n., Choi, O. n., Pham, T. n., Fernandez Vina, M. A., Hoppe, et al
  2020; 12 (528)

- **Editorial: Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation.** *Frontiers in immunology*
  Schneidawind, D. n., Meyer, E. n.
  2020; 11: 523

- **A novel antibody-cell conjugation method to enhance and characterize cytokine-induced killer cells.** *Cytotherapy*
  Frank, M. J., Olsson, N. n., Huang, A. n., Tang, S. W., Negrin, R. S., Elias, J. E., Meyer, E. H.
  2020; 22 (3): 135–43

- **Microtransplantation in Older Patients with AML: A Pilot Study of Safety, Efficacy and Immunologic Effects.** *American journal of hematology*
  Sung, A. D., Jauhari, S. n., Siamakpour-Reihani, S. n., Rao, A. V., Staats, J. n., Chan, C. n., Meyer, E. n., Gadi, V. K., Nixon, A. B., Lyu, J. n., Xie, J. n., Bohannon, L. n., Li, et al
  2020

- **CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.** *Blood*
  Baird, J. H., Frank, M. J., Craig, J. n., Patel, S. n., Spiegel, J. Y., Sahaf, B. n., Oak, J. S., Younes, S. n., Ozawa, M. n., Yang, E. n., Natkunam, Y. n., Tamaresis, J. S., Ehlinger, et al
  2020

- **Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.** *Blood advances*
  Weng, W. K., Arai, S. n., Rezvani, A. n., Johnston, L. n., Lowsky, R. n., Miklos, D. n., Shizuru, J. n., Muffly, L. n., Meyer, E. n., Negrin, R. S., Wang, E. n., Almazan, T. n., Million, et al
  2020; 4 (18): 4474–82

- **Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.** *Bone marrow transplantation*
  Lemieux, C. n., Muffly, L. S., Rezvani, A. n., Lowsky, R. n., Iberri, D. J., Craig, J. K., Frank, M. J., Johnston, L. J., Liedtke, M. n., Negrin, R. n., Weng, W. K., Meyer, E. n., Shizuru, et al
  2020

- **Alloantigen-specific Tr1 cells designed to prevent GvHD have a distinct molecular identity and suppress through CTLA-4 and PD-1** *Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting*
  Cepika, A., Chen, P. P., Uyeda, M. J., Cieniewicz, B., Narula, M., Amaya, L., Louis, D. M., Xu, L., Ji, X., Bertaina, A., Agarwal-Hashmi, R., Davis, M. M., Meyer, et al
  2020: A159–A159

- **Recipient-specific T-cell repertoire reconstitution in the gut following murine hematopoietic cell transplant.** *Blood advances*
  Zheng, P. n., Tamaresis, J. n., Thangavelu, G. n., Xu, L. n., You, X. n., Blazar, B. R., Negrin, R. S., Zehnder, J. L., Iliopoulou, B. P., Meyer, E. H.
  2020; 4 (17): 4232–43

- **Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.** *The Journal of experimental medicine*
  Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., Reddy, S. A., Laport, G. G., Meyer, et al
  2020; 217 (9)

- **Safer HLA mismatch transplantation.** *Blood*
  Meyer, E. n.
  2020; 136 (13): 1472–74

- **Editorial: NKT Cells in Cancer Immunotherapy.** *Frontiers in immunology*
  Webb, T. J., Yuan, W., Meyer, E., Dellabona, P.
  2020; 11: 1314

- **Hyaluronan synthesis inhibition impairs antigen presentation and delays transplantation rejection.** *Matrix biology : journal of the International Society for Matrix Biology*
  Marshall, P. L., Nagy, N. n., Kaber, G. n., Barlow, G. L., Ramesh, A. n., Xie, B. J., Linde, M. H., Haddock, N. L., Lester, C. A., Tran, Q. L., de Vries, C. n., Hargil, A. n., Malkovskiy, et al
  2020

- **Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents**
  Sica, R., Spinner, M. A., Tamaresis, J. S., Advani, R. H., Johnston, L. J., Lowsky, R., Meyer, E. H., Miklos, D. B., Muffly, L. S., Rezvani, A. R., Shizuru, J. A., Weng, W., Negrin, et al
  AMER SOC HEMATOLOGY.2019

- **Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)**
  Schultz, L. M., Muffly, L. S., Spiegel, J. Y., Ramakrishna, S., Hossain, N., Baggott, C., Sahaf, B., Patel, S., Craig, J., Yoon, J., Kadapakkam, M., Majzner, R. G., Frank, et al
  AMER SOC HEMATOLOGY.2019

- **Clonal Evolution and Changes in Two AML Patients Detected with A Novel Single-Cell DNA Sequencing Platform.** *Scientific reports*
  Xu, L., Durruthy-Durruthy, R., Eastburn, D. J., Pellegrino, M., Shah, O., Meyer, E., Zehnder, J.
  2019; 9 (1): 11119

- **Comprehensive Immune Monitoring of Clinical Trials to Advance Human Immunotherapy.** *Cell reports*
  Hartmann, F. J., Babdor, J., Gherardini, P. F., Amir, E. D., Jones, K., Sahaf, B., Marquez, D. M., Krutzik, P., O'Donnell, E., Sigal, N., Maecker, H. T., Meyer, E., Spitzer, et al
  2019; 28 (3): 819

- **Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Narayan, R., Benjamin, J. E., Shah, O., Tian, L., Tate, K., Armstrong, R., Xie, B. J., Lowsky, R., Laport, G., Negrin, R. S., Meyer, E. H.
  2019; 25 (7): 1293–1303

- **Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients** *JCI INSIGHT*
  Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., Tang, S., Baker, J., Armstrong, R., Tate, K., Tadisco, C., Arai, S., Johnston, et al
  2019; 4 (10)

- **Dose-Intense BCNU/Melphalan Regimen Followed By Autologous Hematopoietic Cell Transplantation (AHCT) Results in Prolonged PFS in Myeloma Patients**

Gandhi, A., Rezvani, A., Lowsky, R., Johnston, L., Shizuru, J. A., Miklos, D. B., Arai, S., Muffly, L., Meyer, E. H., Negrin, R. S., Weng, W.
ELSEVIER SCIENCE INC.2019

- **A Proinflammatory Invariant Natural Killer T Cell Phenotypic State Associates with Human Graft-Versus-Host Disease Onset**
  Xie, B. J., Erkers, T., Kenyon, L., Rieck, M., Basina, M., Jensen, K., Strober, S., Negrin, R. S., Maecker, H. T., Meyer, E. H.
  ELSEVIER SCIENCE INC.2019

- **Donor-derived CIK Cell Infusion as Consolidation after Non-myeloablative Allogeneic Transplant for Myeloid Neoplasms.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
  Narayan, R. n., Benjamin, J. E., Shah, O. n., Tian, L. n., Tate, K. n., Armstrong, R. n., Xie, B. n., Lowsky, R. n., Laport, G. n., Negrin, R. S., Meyer, E. H.
  2019

- **Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.** *JCI insight*
  Meyer, E. H., Laport, G. n., Xie, B. J., MacDonald, K. n., Heydari, K. n., Sahaf, B. n., Tang, S. W., Baker, J. n., Armstrong, R. n., Tate, K. n., Tadisco, C. n., Arai, S. n., Johnston, et al
  2019; 4 (10)

- **Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin.** *PloS one*
  Narayan, R. n., Olsson, N. n., Wagar, L. E., Medeiros, B. C., Meyer, E. n., Czerwinski, D. n., Khodadoust, M. S., Zhang, L. n., Schultz, L. n., Davis, M. M., Elias, J. E., Levy, R. n.
  2019; 14 (7): e0219547

- **Optimization and characterization of calcium phosphate transfection in mesenchymal stem cells.** *Tissue engineering. Part C, Methods*
  Lo, C. W., Lin, T. H., Ueno, M. n., Romero-Lopez, M. n., Maruyama, M. n., Kohno, Y. n., Rhee, C. n., Yao, Z. n., Pérez-Cruz, M. n., Meyer, E. n., Goodman, S. B.
  2019

- **Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.** *JCI insight*
  Meyer, E. H., Laport, G. n., Xie, B. J., MacDonald, K. n., Heydari, K. n., Sahaf, B. n., Tang, S. W., Baker, J. n., Armstrong, R. n., Tate, K. n., Tadisco, C. n., Arai, S. n., Johnston, et al
  2019; 4 (10)

- **Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin.** *PloS one*
  Narayan, R. n., Olsson, N. n., Wagar, L. E., Medeiros, B. C., Meyer, E. n., Czerwinski, D. n., Khodadoust, M. S., Zhang, L. n., Schultz, L. n., Davis, M. M., Elias, J. E., Levy, R. n.
  2019; 14 (7): e0219547

- **A Proinflammatory Invariant Natural Killer T Cells Phenotypic State Associates with Human Graft-Versus-Host Disease Onset and Response**
  Erkers, T., Xei, B., Kenyon, L., Rieck, M., Basina, M., Jensen, K., Strober, S., Negrin, R. S., Maecker, H. T., Meyer, E. H.
  AMER SOC HEMATOLOGY.2018

- **Relationship Between Mixed Chimerism and Acceptance of HLA-matched and -Mismatched Kidney Transplants after Withdrawal of Immunosuppressive Drugs**
  Busque, S., Scandling, J., Lowsky, R., Shizuru, J., Jensen, K., Shori, A., Hoppe, R., Engleman, E., Meyer, E., Strober, S.
  LIPPINCOTT WILLIAMS & WILKINS.2018: S393

- **ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Hashmi, S. K., Lee, S. J., Savani, B. N., Burns, L., Wingard, J. R., Perales, M., Palmer, J., Chow, E., Meyer, E., Marks, D., Mohty, M., Inamoto, Y., Rodriguez, et al
  2018; 24 (6): 1119–24

- **Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation** *BLOOD ADVANCES*
  Muffly, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., Miklos, D., Arai, S., Shizuru, J., Johnston, L., Meyer, E., Weng, W., Laport, et al
  2018; 2 (6): 681–90

- **IL-2 Plus IL-15 Leads to Enhanced Ex Vivo Expansion of Human Invariant Natural Killer T Cells**
  Mayers, M., Simonetta, F., Lee, A. W., Hirai, T., Maas-Bauer, K., Alvarez, M., Turkoz, M., Baker, J., Meyer, E., Negrin, R. S.

ELSEVIER SCIENCE INC.2018: S166–S167

- **Bone Morphogenetic Protein Signaling Pathway Modulation by Blocking Anti-Repulsive Guidance Molecule B Antibody Promotes Tolerance in Graft-Versus-Host Disease**
  Cruz, M., Hsu, K., Iliopoulou, B. P., Erkers, T., Pang, W., Dekruyff, R. H., Freeman, G. J., Meyer, E.
  ELSEVIER SCIENCE INC.2018: S324

- **Quantifying genetic susceptibility in T1DM-implications for diagnosis after age 30** *NATURE REVIEWS ENDOCRINOLOGY*
  Meyer, E., Maahs, D. M.
  2018; 14 (3): 134–35

- **Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., Meyer, E., Muffly, L., Negrin, R., Rezvani, A., Shizuru, J., Weng, W., Johnston, et al
  2017; 23 (10): 1744–48

- **Repertoire of Murine T Cells in Target Tissues of MHC-Matched and -Mismatched Graft-Versus-Host Disease**
  Zheng, P., You, X., Tamaresis, J., Xu, L., Hsu, K., Than, R., Iliopoulou, B. P., Pierini, A., Schneidawind, D., Zehnder, J. L., Blazar, B. R., Negrin, R. S., Meyer, et al
  ELSEVIER SCIENCE INC.2017: S307–S308

- **Methodologic Considerations in the Application of Next-Generation Sequencing of Human TRB Repertoires for Clinical Use** *JOURNAL OF MOLECULAR DIAGNOSTICS*
  Xu, L., You, X., Zheng, P., Zhang, B. M., Gupta, P. K., Lavori, P., Meyer, E., Zehnder, J. L.
  2017; 19 (1): 72-83

- **HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.** *Blood advances*
  Spinner, M. A., Fernández-Viña, M. n., Creary, L. E., Quinn, O. n., Elder, L. n., Arai, S. n., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Shizuru, J. A., Weng, et al
  2017; 1 (17): 1347–57

- **T cells expressing chimeric antigen receptor promote immune tolerance.** *JCI insight*
  Pierini, A. n., Iliopoulou, B. P., Peiris, H. n., Pérez-Cruz, M. n., Baker, J. n., Hsu, K. n., Gu, X. n., Zheng, P. P., Erkers, T. n., Tang, S. W., Strober, W. n., Alvarez, M. n., Ring, et al
  2017; 2 (20)

- **Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors**
  Spinner, M. A., Vina, M., Elder, L., Arai, S., Johnston, L., Meyer, E., Miklos, D., Muffly, L., Negrin, R. S., Shizuru, J., Weng, W., Laport, G. G., Strober, et al
  AMER SOC HEMATOLOGY.2016

- **A Phase I Study of Donor Regulatory T Cells As Treatment for Steroid Dependent/Refractory Chronic Graft Versus Host Disease**
  Johnston, L., Armstrong, R., Baker, J., Sahaf, B., Otani, J., Tate, K., Tudisco, C., Sheehan, K., Meyer, E., Miklos, D., Negrin, R. S.
  AMER SOC HEMATOLOGY.2016

- **The Use of Monoclonal Antibody Directed Chimeric Antigen Receptors to Facilitate Conventional T Cell and Treg Control of GvHD and Tissue Tolerance in Murine Models**
  Pierini, A., Iliopoulou, B., Peiris, H., Cruz, M., Baker, J., Hsu, K., Strober, W., Zheng, P., Erkers, T., Ring, A., Velardi, A., Negrin, R. S., Kim, et al
  AMER SOC HEMATOLOGY.2016

- **Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation**
  Muffly, L. S., Sheehan, K., Armstrong, R., Tate, K., Tudisco, C., Rezvani, A. R., Miklos, D., Arai, S., Shizuru, J., Johnston, L., Meyer, E., Weng, W., Laport, et al
  AMER SOC HEMATOLOGY.2016

- **TNF-a priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment.** *Blood*
  Pierini, A., Strober, W., Moffett, C., Baker, J., Nishikii, H., Alvarez, M., Pan, Y., Schneidawind, D., Meyer, E., Negrin, R. S.

2016; 128 (6): 866-871

- **Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation.**
  Veeraputhiran, M., Arai, S., Lowsky, R., Miklos, D., Meyer, E., Muffly, L. S., Negrin, R., Rezvani, A. R., Shizuru, J., Weng, W., Johnston, L. J.
  AMER SOC CLINICAL ONCOLOGY.2016
- **Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma.**
  Neppalli, A., Shizuru, J., Johnston, L. J., Muffly, L. S., Weng, W., Negrin, R., Meyer, E., Laport, G., Lowsky, R., Arai, S., Miklos, D., Rezvani, A. R.
  AMER SOC CLINICAL ONCOLOGY.2016
- **Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin**
  Nakasone, H., Miklos, D. B., Meyer, E., Rezvani, A., Muffly, L., Weng, W., Arai, S., Johnston, L., Laport, G. G., Shizuru, J. A., Negrin, R., Strober, S., Lowsky, et al
  ELSEVIER SCIENCE INC.2016: S204–S205
- **TIM-1 Blockade of the Donor Graft Provides Protection Against Lethal Gvhd**
  Iliopoulou, B. P., Hsu, K., Pierini, A., Freeman, G. J., Dekruyff, R. H., Meyer, E.
  ELSEVIER SCIENCE INC.2016: S398-S399
- **The Use of Monoclonal Antibody Directed Chimeric Antigen Receptors to Guide T Cell and Treg Homing for GvHD Control and Tissue Tolerance in Murine Models**
  Pierini, A., Iliopoulou, B. P., Baker, J., Peiris, H., Hsu, K., Kim, S., Negrin, R., Meyer, E.
  ELSEVIER SCIENCE INC.2016: S88–S89
- **TNF-Alpha Priming Enhances CD4+FoxP3+Regulatory T Cell Suppressive Function in GVHD Prevention and Treatment**
  Pierini, A., Strober, W. A., Moffett, C., Baker, J., Nishikii, H., Pan, Y., Alvarez, M., Schneidawind, D., Meyer, E., Negrin, R.
  ELSEVIER SCIENCE INC.2016: S144–S145
- **Freeze and Thaw of CD4(+) CD25(+) Foxp3(+) Regulatory T Cells Results in Loss of CD62L Expression and a Reduced Capacity to Protect against Graft-versus-Host Disease** *PLOS ONE*
  Florek, M., Schneidawind, D., Pierini, A., Baker, J., Armstrong, R., Pan, Y., Leveson-Gower, D., Negrin, R., Meyer, E.
  2015; 10 (12)
- **Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms**
  Narayan, R., Benjamin, J., Laport, G., Tian, L., Tate, K., Elder, L., Galvez, L., Armstrong, R., Sheehan, K., Lowsky, R., Arai, S., Johnston, L., Miklos, et al
  AMER SOC HEMATOLOGY.2015
- **Increased Activity in the T Cell Effector Phase and Enhanced T Cell Repertoire Target-Tissue Stability Distinguish Alloreactivity Across Major Versus Minor Histocompatibility Barriers**
  Zheng, P., Vasey, A. E., Baker, J., Iliopoulou, B., Leveson-Gower, D. B., Pierini, A., Schneidawind, D., You, X., Hsu, K., Negrin, R., Meyer, E.
  AMER SOC HEMATOLOGY.2015
- **TNF-Alpha Priming Enhances CD4(+) FoxP3(+) Regulatory T Cell Suppressive Function in GvHD Prevention and Treatment**
  Pierini, A., Moffett, C., Schneidawind, D., Baker, J., Nishikii, H., Pan, Y., Alvarez, M., Meyer, E., Negrin, R.
  AMER SOC HEMATOLOGY.2015
- **Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients**
  Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Ajib, S., de Fontbrune, et al
  AMER SOC HEMATOLOGY.2015
- **Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis**
  Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., Advani, R. H., Gupta, N. K., Laport, G., Maeda, L. S., Meyer, E., Miklos, D. B., Negrin, et al
  AMER SOC HEMATOLOGY.2015
- **Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy.** *Haematologica*
  Nakasone, H., Remberger, M., Tian, L., Brodin, P., Sahaf, B., Wu, F., Mattsson, J., Lowsky, R., Negrin, R., Miklos, D. B., Meyer, E.

2015; 100 (11): 1477-1485

- **CMV after transplant: T-cell repertoire crooks.** *Blood*
  Meyer, E.
  2015; 125 (25): 3827-8
- **Third-party CD4(+) invariant natural killer T cells protect from murine GVHD lethality** *BLOOD*
  Schneidawind, D., Baker, J., Pierini, A., Buechele, C., Luong, R. H., Meyer, E. H., Negrin, R. S.
  2015; 125 (22): 3491-3500
- **Deep profiling of single T cell receptor repertoire and phenotype with targeted RNA-seq**
  Ji, X., Lyu, S., Spindler, M., Bacchetta, R., Goncharov, I., Han, A., Glanville, J., Wang, W., Roncarolo, M., Meyer, E., Nadeau, K., Maecker, H.
  AMER ASSOC IMMUNOLOGISTS.2015
- **Third Party Invariant Natural Killer T Cells Protect from Lethal Graft-Versus-Host Disease through Donor CD4+CD25+FoxP3+Regulatory T Cells**
  Schneidawind, D., Pierini, A., Baker, J., Buechele, C., Luong, R., Meyer, E., Negrin, R.
  ELSEVIER SCIENCE INC.2015: S60
- **Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Strategy**
  Nakasone, H., Remberger, M., Tian, L., Brodin, P., Sahaf, B., Wu, F., Mattsson, J., Lowsky, R., Negrin, R., Miklos, D. B., Meyer, E.
  ELSEVIER SCIENCE INC.2015: S340–S341
- **Loss of CD62L Expression in CD4+FoxP3+Regulatory T Cells Following Freeze-and-Thaw Prevents Protection Against GVHD in Murine Models**
  Florek, M., Schneidawind, D., Baker, J., Pierini, A., Leveson-Gower, D. B., Pan, Y., Negrin, R. S., Meyer, E. H.
  AMER SOC HEMATOLOGY.2014
- **Use of High-Throughput Sequencing (HTS) of TCR beta to Determine the Kinetics of Graft-Versus-Lymphoma (GVL) Effect and T-Cell Repertoire Profiles after Allogeneic Transplant**
  Weng, W., Armstrong, R., Arai, S., Hoppe, R. T., Meyer, E. H., Kim, Y. H.
  AMER SOC HEMATOLOGY.2014
- **Third Party Invariant Natural Killer T Cells Protect from Graft-Versus-Host Disease Lethality through Expansion of Donor CD4(+)FoxP3(+) Regulatory T Cells**
  Schneidawind, D., Baker, J., Buechele, C., Meyer, E. H., Negrin, R. S.
  AMER SOC HEMATOLOGY.2014
- **Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Intensity**
  Nakasone, H., Remberger, M., Tian, L., Brodin, P., Sahaf, B., Wu, F., Lowsky, R., Mattsson, J., Negrin, R. S., Miklos, D. B., Meyer, E.
  AMER SOC HEMATOLOGY.2014
- **CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells.** *Blood*
  Schneidawind, D., Pierini, A., Alvarez, M., Pan, Y., Baker, J., Buechele, C., Luong, R. H., Meyer, E. H., Negrin, R. S.
  2014; 124 (22): 3320-3328
- **Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models** *BLOOD*
  Florek, M., Sega, E. I., Leveson-Gower, D. B., Baker, J., Mueller, A. M., Schneidawind, D., Meyer, E., Negrin, R. S.
  2014; 124 (11): 1832-1842
- **Memory regulatory T cells reside in human skin** *JOURNAL OF CLINICAL INVESTIGATION*
  Rodriguez, R. S., Pauli, M. L., Neuhaus, I. M., Yu, S. S., Arron, S. T., Harris, H. W., Yang, S. H., Anthony, B. A., Sverdrup, F. M., Krow-Lucal, E., MacKenzie, T. C., Johnson, D. S., Meyer, et al
  2014; 124 (3): 1027-1036
- **CD4(+) Invariant Natural Killer T Cells Protect from Acute Graft-Versus-Host Disease Lethality through a Dramatic Expansion of Donor-Derived CD4(+)FoxP3(+) Regulatory T Cells**
  Schneidawind, D., Pierini, A., Alvarez, M., Pan, Y., Baker, J., Kim, B., Nishikii, H., Buechele, C., Meyer, E., Negrin, R.
  ELSEVIER SCIENCE INC.2014: S23

- **Outcome of Tandem Autologous/Allogeneic Hematopoietic Cell Transplantation in High-Risk Non Hodgkin's Lymphoma Patients: Stanford University Experience**
  Wudhikarn, K., Lavori, P., Arai, S., Johnston, L., Laport, G. G., Lowsky, R., Miklos, D. B., Shizuru, J. A., Hoppe, R. T., Benjamin, J., Meyer, E., Negrin, R., Weng, et al
  ELSEVIER SCIENCE INC.2014: S164

- **Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance.** *Nature communications*
  de Almeida, P. E., Meyer, E. H., Kooreman, N. G., Diecke, S., Dey, D., Sanchez-Freire, V., Hu, S., Ebert, A., Odegaard, J., Mordwinkin, N. M., Brouwer, T. P., Lo, D., Montoro, et al
  2014; 5: 3903-?

- **CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells** *BLOOD*
  Schneidawind, D., Pierini, A., Alvarez, M., Pan, Y., Baker, J., Buechele, C., Luong, R. H., Meyer, E. H., Negrin, R. S.
  2014

- **Prevalence of graft versus host disease and cytomegalovirus infection in patients post-haematopoietic cell transplantation presenting with gastrointestinal symptoms.** *Alimentary pharmacology & therapeutics*
  Liu, A., Meyer, E., Johnston, L., Brown, J., Gerson, L. B.
  2013; 38 (8): 955-966

- **A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease.** *Blood*
  Meyer, E. H., Hsu, A. R., Liliental, J., Löhr, A., Florek, M., Zehnder, J. L., Strober, S., Lavori, P., Miklos, D. B., Johnson, D. S., Negrin, R. S.
  2013; 121 (24): 4955-4962

- **A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease** *BLOOD*
  Meyer, E. H., Hsu, A. R., Liliental, J., Loehr, A., Florek, M., Zehnder, J. L., Strober, S., Lavori, P., Miklos, D. B., Johnson, D. S., Negrin, R. S.
  2013; 121 (24): 4955-4962

- **Massively parallel phenotyping and clonotyping of single T cells**
  Johnson, D., Conant, C., Withey, G., Lohr, A., Hsu, A., Meyer, E.
  AMER ASSOC IMMUNOLOGISTS.2013

- **Repertoire-wide single-cell linked immunoglobulin DNA libraries**
  Johnson, D., Conant, C., Withey, G., Lhr, A., Hsu, A., Meyer, E.
  AMER ASSOC IMMUNOLOGISTS.2013

- **Yield of Single versus Upper and Lower Endoscopic Biopsies in the Diagnosis of Gastrointestinal Graft-Versus-Host Disease in Patients with Prior Allogeneic Hematopoietic Stem Cell Transplantation**
  Liu, A., Meyer, E., Johnston, L., Gerson, L.
  NATURE PUBLISHING GROUP.2012: S731

- **Apoptotic Cells Activate NKT Cells through T Cell Ig-Like Mucin-Like-1 Resulting in Airway Hyperreactivity** *JOURNAL OF IMMUNOLOGY*
  Lee, H., Meyer, E. H., Goya, S., Pichavant, M., Kim, H. Y., Bu, X., Umetsu, S. E., Jones, J. C., Savage, P. B., Iwakura, Y., Casasnovas, J. M., Kaplan, G., Freeman, et al
  2010; 185 (9): 5225-5235

- **Activation of nonclassical CD1d-restricted NK T cells induces airway hyperreactivity in beta(2)-microglobulin-deficient mice** *JOURNAL OF IMMUNOLOGY*
  Koh, Y. I., Kim, H. Y., Meyer, E. H., Pichavant, M., Akbari, O., Yasumi, T., Savage, P. B., DeKruyff, R. H., Umetsu, D. T.
  2008; 181 (7): 4560-4569

- **ICOS/ICOSL interaction is required for CD4(+) invariant NKT cell function and homeostatic survival** *JOURNAL OF IMMUNOLOGY*
  Akbari, O., Stock, P., Meyer, E. H., Freeman, G. J., Sharpe, A. H., Umetsu, D. T., DeKruyff, R. H.
  2008; 180 (8): 5448-5456

- **Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17** *JOURNAL OF EXPERIMENTAL MEDICINE*
  Pichavant, M., Goya, S., Meyer, E. H., Johnston, R. A., Kim, H. Y., Matangkasombut, P., Zhu, M., Iwakura, Y., Savage, P. B., DeKruyff, R. H., Shore, S. A., Umetsu, D. T.

2008; 205 (2): 385-393

- **T cells and NKT cells in the pathogenesis of asthma** *ANNUAL REVIEW OF MEDICINE*
  Meyer, E. H., DeKruyff, R. H., Umetsu, D. T.
  2008; 59: 281-292

- **Delirium following abrupt discontinuation of fluoxetine** *CLINICAL NEUROLOGY AND NEUROSURGERY*
  Blum, D., Maldonado, J., Meyer, E., Lansberg, M.
  2008; 110 (1): 69-70

- **Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17** *8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies*
  Pichavant, M., Goya, S., Meyer, E., Johnston, R., Kim, H., Matangkasombut, P., Zhu, M., Iwakura, Y., Savage, P., DeKruyff, R., Shore, S., Umetsu, D.
  ACADEMIC PRESS INC ELSEVIER SCIENCE.2008: S38–S38

- **INKT cells require CCR4 to localize to the airways and to induce airway hyperreactivity** *JOURNAL OF IMMUNOLOGY*
  Meyer, E. H., Wurbel, M., Staton, T. L., Pichavant, M., Kan, M. J., Savage, P. B., DeKruyff, R. H., Butcher, E. C., Campbell, J. J., Umetsu, D. T.
  2007; 179 (7): 4661-4671

- **iNKT cells in allergic disease** *T CELL ACTIVATION BY CD1 AND LIPID ANTIGENS*
  Meyer, E. H., DeKruyff, R. H., Umetsu, D. T.
  2007; 314: 269-291

- **Natural killer T cells regulate the development of asthma** *INTERNATIONAL REVIEWS OF IMMUNOLOGY*
  Umetsu, D. T., Meyer, E. H., DeKruyff, R. H.
  2007; 26 (1-2): 121-140

- **CD1d restricted natural killer T cells are not required for allergic skin inflammation** *JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY*
  Elkhal, A., Pichavant, M., He, R., Scott, J., Meyer, E., Goya, S., Geha, R. S., Umetsu, D. T.
  2006; 118 (6): 1363-1368

- **Medicine on a need-to-know basis** *NATURE IMMUNOLOGY*
  Busch, R., Byrne, B., Gandrud, L., Sears, D., Meyer, E., Kattah, M., Kurihara, C., Haertel, E., Parnes, J. R., Mellins, E. D.
  2006; 7 (6): 543-547

- **Glycolipid activation of invariant T cell receptor(+) NK T cells is sufficient to induce airway hyperreactivity independent of conventional CD4(+) T cells** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
  Meyer, E. H., Goya, S., Akbari, O., Berry, G. J., Savage, P. B., Kronenberg, M., Nakayama, T., DeKruyff, R. H., Umetsu, D. T.
  2006; 103 (8): 2782-2787

- **iNKT-Cells require CCR4 binding of CCL17 to localize to the airways where they are necessary and sufficient for inducing airway hyperreactivity.** *6th Annual Meeting of the Federation-of-Clinical-Immunology-Societies*
  Meyer, E., Wurbel, M., Staton, T., Savage, P., DeKruyff, R., Campbell, J., Butcher, E., Umetsu, D.
  ACADEMIC PRESS INC ELSEVIER SCIENCE.2006: S22–S22

- **Glycolipid mediated activation of iNKT cells is sufficient to induce airway hyperreactivity independent of conventional CD4 T cells.** *5th Annual Meeting of the Federation-of-Clinical-Immunology-Societies*
  Meyer, E. H., Akbari, O., Berry, G., Savage, P., DeKruyff, R. H., Umetsu, D. T.
  ACADEMIC PRESS INC ELSEVIER SCIENCE.2005: S14–S15

- **Adaptation at specific loci. VII. Natural selection, dispersal and the diversity of molecular-functional variation patterns among butterfly species complexes (Colias : Lepidoptera, Pieridae)** *MOLECULAR ECOLOGY*
  Watt, W. B., Wheat, C. W., Meyer, E. H., Martin, J. F.
  2003; 12 (5): 1265-1275

- **Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity** *NATURE MEDICINE*
  Akbari, O., Stock, P., Meyer, E., Kronenberg, M., Sidobre, S., Nakayama, T., Taniguchi, M., Grusby, M. J., DeKruyff, R. H., Umetsu, D. T.
  2003; 9 (5): 582-588

- **CD4 T-helper cells engineered to produce IL-10 prevent allergen-induced airway hyperreactivity and inflammation** *JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY*

Oh, J. W., Seroogy, C. M., Meyer, E. H., Akbari, O., Berry, G., Fathman, C. G., DeKruyff, R. H., Umetsu, D. T.
2002; 110 (3): 460-468

- **Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity** *NATURE MEDICINE*
  Akbari, O., Freeman, G. J., Meyer, E. H., Greenfield, E. A., Chang, T. T., Sharpe, A. H., Berry, G., DeKruyff, R. H., Umetsu, D. T.
  2002; 8 (9): 1024-1032